Registry following adults with advanced colorectal cancer after two prior treatments
Records treatments and outcomes in adults with spread colorectal cancer after two prior therapies.
Key facts
- Who runs it
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Where
- Linz, Rankweil, Salzburg, Steyr, Wels, and Zams, AustriaSee the 7 sites
- Trial code
- Registry title
- AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond
- Status
- Recruiting
- People taking part
- 500 people, planned
- Started
- 31 Oct 2024
- Expected to end
- Dec 2034
- Type of study
- Observational
- Record updated
- 10 April 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The registry is looking for adults with metastatic colorectal cancer, confirmed by a tissue sample, who have already had at least two lines of treatment for advanced disease.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Metastatic colorectal cancer (mCRC), diagnosed from tissue
- Earlier treatment
- At least 2 earlier lines of palliative systemic therapy, including 5-FU, irinotecan, oxaliplatin, anti-VEGF, anti-EGFR (if RAS/BRAF wildtype) and anti-PD1 therapy (if MSI/MMRd). People who had mFOLFOXIRI with or without anti-VEGF or anti-EGFR as first treatment, or who cannot receive 5-FU, oxaliplatin or irinotecan, can join after first-line treatment.
Main reasons for not taking part
- No specific exclusion criteria, because this registry is non-interventional
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- patients ≥ 18 years with tissue-based diagnosis of mCRC
- ≥ 2 prior lines of palliative systemic therapy including 5-FU, irinotecan, oxaliplatin, anti-VEGF, anti-EGFR (in case of RAS/BRAF wildtype), anti-PD1- therapy (in case of MSI/MMRd) . (Exception: Patients who have received mFOLFOXIRI +/- anti-VEGF or anti- EGFR- 1L therapy or patients with ineligibility to receive 5-FU, oxaliplatin or irinotecan can be included after 1st line.)
Who cannot take part
- Due to the non-interventional design of this registry, there are no specific exclusion criteria
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
The criteria questions were written by an AI system from the criteria published for NCT06678919. Checked by software, not by a doctor.
- How many different drug treatment plans (such as chemotherapy) have you had for cancer that has spread?
This trial is currently available in Austria.
- KUK Linz - Med Campus III.: Univ.-Klinik für Hämatologie und Internistische OnkologieLinz, AustriaContact: Clemens Schmitt, MD (principal investigator)Taking people
- Ordensklinikum Linz, BHS - Interne ILinz, AustriaContact: Holger Rumpold, MD (principal investigator)Taking people
- LKH Feldkirch: Innere Medizin II/ Interne E (Hämatologie und Onkologie)Rankweil, AustriaContact: Thomas Winder, MD (principal investigator)Taking people
- Department of Internal Medicine III, Paracelsus Medical University SalzburgSalzburg, AustriaContact: Florian Huemer, Priv.Doz. DrTaking people
- Klinikum Steyr: Innere Medizin II: Onkologie, Gastroenterologie, AngiologieSteyr, AustriaContact: Georg Schreil, MD (principal investigator)Taking people
- Klinikum Wels: Abteilung für Innere Medizin IVWels, AustriaContact: Sonja Heibl, MD (principal investigator)Taking people
- KH Zams: Innere Medizin Internistische Onkologie und HämatologieZams, AustriaContact: Ewald Wöll, MD (principal investigator)Taking people
About the trial
What the trial wants to find out
Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States and Europe. Although selected patients with oligometastatic CRC undergo systemic therapy and surgery/local ablative therapy in curative intent, the treatment approach for the majority of metastatic CRC (mCRC) patients remains palliative with a median overall survival (OS) ranging between 9-38 months depending on various prognostic and predictive factors. Particularly in advanced stages (in the third line of therapy and beyond), interesting and promising results have recently been achieved with various treatment approaches. The aim of this registry is to establish a disease-specific registry to evaluate the treatment landscape of patients with mCRC who have already received at least two lines of therapy.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond
- Plain-language title
- Registry following adults with advanced colorectal cancer after two prior treatmentsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT06678919, who can take part
- Publications
- Record updated
- 10 April 2025